نتایج جستجو برای: serms

تعداد نتایج: 327  

Journal: :Reproductive biology and endocrinology : RB&E 2003
Denis Stygar Natalia Muravitskaya Britt Eriksson Håkan Eriksson Lena Sahlin

BACKGROUND Selective estrogen receptor modulators (SERMs) have been developed in order to create means to control estrogenic effects on different tissues. A major drawback in treatment of estrogen receptor (ER) positive breast cancer with the antagonist tamoxifen (TAM) is its agonistic effect in the endometrium. Raloxifene (RAL) is the next generation of SERMs where the agonistic effect on the ...

Journal: :The Journal of steroid biochemistry and molecular biology 2006
Dalia Somjen Gary H Posner Naftali Stern

Vitamin D receptors are widely expressed in the cardiovascular system, in which Vitamin D and its metabolites exert a variety of biological activities such as regulation of cellular proliferation and differentiation, cell calcium transients and cell energy metabolism in vitro. The latter is mediated through the control of the brain type creatine kinase specific activity (CK), which serves to pr...

2000
ROBERT A. SHAPIRO CONG XU DANIEL M. DORSA

Neuronal expression of vasopressin messenger RNA (mRNA) and peptide has been shown to be estrogen dependent. A 5.5-kb genomic DNA fragment, 59 of the AVP coding region, was used in luciferase reporter assays to measure transcriptional activation by either estrogen receptor a or b in response to various treatments. ERa and ERb displayed differential regulation of the AVP promoter. SK-N-SH cells ...

2016
Xue-Lian Chen Feng Du Ruo-Xi Hong Jia-Yu Wang Yang Luo Qing Li Ying Fan Bing-He Xu

BACKGROUND Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing regimens. However, no clinical trials have directly compared the efficacy of MCT and HT after response to first-line capecitabine-based combination chemothera...

Journal: :Endocrine-related cancer 2004
Oliver Zierau Jacintha O'Sullivan Colm Morrissey Dana McDonald Winfried Wünsche Martin R Schneider Martin P Tenniswood Günter Vollmer

Tamoxifen is the most widely prescribed anti-neoplastic drug for the treatment of both localized and metastatic breast cancer. It is also the prototype for a class of drugs that are referred to as selective estrogen receptor modifiers (SERMs), most of which have both estrogenic and anti-estrogenic activity in estrogen target tissues including the breast and endometrium. The underlying mechanism...

Journal: :Molecular endocrinology 2010
Gianpaolo Rando David Horner Andrea Biserni Balaji Ramachandran Donatella Caruso Paolo Ciana Barry Komm Adriana Maggi

Using a mouse model engineered to measure estrogen receptor (ER) transcriptional activity in living organisms, we investigated the effect of long-term (21 d) hormone replacement on ER signaling by whole-body in vivo imaging. Estrogens and selective ER modulators were administered daily at doses equivalent to those used in humans as calculated by the allometric approach. As controls, ER activity...

2001
John F. Robertson Robert I. Nicholson Nigel J. Bundred Elizabeth Anderson Zenon Rayter Mitchell Dowsett John N. Fox Julia M. W. Gee Alan Webster Alan E. Wakeling Charles Morris Michael Dixon

7 -[9-(4,4,5,5,5-Pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene3,17 -diol (ICI 182,780; Faslodex) is a novel steroidal antiestrogen. This partially blind, randomized, multicenter study compared the effects of single doses of long-acting ICI 182,780 with tamoxifen or placebo on estrogen receptor (ER ) and progesterone receptor (PgR) content, Ki67 proliferation-associated antigen label...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید